About: Research Progress of Drug Treatment in Novel Coronavirus Pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Research Progress of Drug Treatment in Novel Coronavirus Pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Research Progress of Drug Treatment in Novel Coronavirus Pneumonia
Creator	Fan, Hua Huang, Jiarui Liu, Anran Wu, Jiannan Yan, Junqiang
Source	Medline; PMC
abstract	As of March 10, 2020, more than 100,000 novel coronavirus pneumonia cases have been confirmed globally. With the continuous spread of the new coronavirus pneumonia epidemic in even the world, prevention and treatment of the disease have become urgent tasks. The drugs currently being developed are not adequate to deal with this critical situation. In addition to being controlled through effective isolation, we need a rapid response from the healthcare and biotechnology industries to accelerate drug treatment research. By reviewing the currently available literature published at home and abroad, we summarize the current research progress of drug treatment during the epidemic period. At present, the drugs that can be used for treatment mainly include antiviral drugs, antimalarials, glucocorticoids, plasma therapy, biological agents, and traditional Chinese medicine. The effectiveness and safety of drug therapy need to be confirmed by more clinical studies.
has issue date	2020-05-13(xsd:dateTime)
bibo:doi	10.1208/s12249-020-01679-z
bibo:pmid	32405780
has license	no-cc
sha1sum (hex)	4583c985946b9e5753ba1618232635aac64e6ce2
schema:url	https://doi.org/10.1208/s12249-020-01679-z
resource representing a document's title	Research Progress of Drug Treatment in Novel Coronavirus Pneumonia
has PubMed Central identifier	PMC7220569
has PubMed identifier	32405780
schema:publication	AAPS PharmSciTech
resource representing a document's body	covid:4583c985946b9e5753ba1618232635aac64e6ce2#body_text
is schema:about of	named entity 'effective' named entity 'biotechnology' named entity 'drug therapy' named entity 'biological agents' named entity 'Novel' named entity 'BIOLOGICAL AGENTS' named entity 'MORE THAN' named entity 'USED' named entity 'NEW' named entity 'EPIDEMIC PERIOD' named entity 'SITUATION' named entity 'CRITICAL' named entity 'GLUCOCORTICOIDS' named entity 'CLINICAL STUDIES' named entity 'MARCH' named entity 'CONTINUOUS' named entity 'TREATMENT' named entity 'URGENT' named entity 'RESEARCH' covid:arg/4583c985946b9e5753ba1618232635aac64e6ce2 named entity 'human infection' named entity 'nitazoxanide' named entity '2019-nCoV' named entity '2019-nCoV' named entity 'immunoglobulin' named entity 'MERS' named entity 'neuraminidase inhibitors' named entity 'ritonavir' named entity 'severe acute respiratory syndrome' named entity 'glucocorticoids' named entity 'lopinavir/ritonavir' named entity 'epidemic' named entity 'antibody' named entity 'safety' named entity 'drug treatment' named entity 'interferon-β' named entity 'ribavirin' named entity 'peptides' named entity 'drug research' named entity 'pneumonia' named entity 'vaccines' named entity '2019-nCoV' named entity 'bronchoalveolar lavage fluid' named entity 'peramivir' named entity 'SARS' named entity '2019-nCoV' named entity 'interferon' named entity 'monoclonal antibodies' named entity 'antivirals' named entity 'public health emergency' named entity '2019-nCoV' named entity 'Bupleurum' named entity 'dyspnea' named entity 'glycoprotein' named entity 'recovery period' named entity '2019-nCoV' named entity 'continuous' named entity 'developed' named entity 'prevention' named entity 'pneumonia' named entity 'epidemic' named entity 'current research' named entity 'epidemic' named entity 'traditional Chinese medicine' named entity 'coronavirus' named entity 'drug treatment' named entity 'coronavirus' named entity '2, 3' named entity 'pneumonia' named entity 'corticosteroids' named entity 'biological agents' named entity 'angiotensin-converting enzyme' named entity '2019-nCoV' named entity 'interferon' named entity 'bat' named entity 'antivirals' named entity 'HCoV-229E'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software